$CDXC
ChromaDex Corp.

2021 Q4 Form 10-K Financial Statement

#000162828022006041 Filed on March 14, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $17.76M $67.45M $15.45M
YoY Change 14.94% 13.82% 18.03%
Cost Of Revenue $6.891M $25.96M $6.020M
YoY Change 14.47% 8.24% 7.12%
Gross Profit $10.87M $41.49M $9.420M
YoY Change 15.37% 17.62% 26.1%
Gross Profit Margin 61.2% 61.51% 60.97%
Selling, General & Admin $15.14M $64.73M $14.51M
YoY Change 4.33% 25.17% -4.48%
% of Gross Profit 139.3% 156.02% 154.03%
Research & Development $1.045M $3.832M $990.0K
YoY Change 5.56% 12.21% -13.16%
% of Gross Profit 9.62% 9.24% 10.51%
Depreciation & Amortization $262.0K $890.0K $280.0K
YoY Change -6.43% 2.18% 3.7%
% of Gross Profit 2.41% 2.15% 2.97%
Operating Expenses $16.18M $68.56M $15.51M
YoY Change 4.35% 24.37% -5.02%
Operating Profit -$5.316M -$27.07M -$6.090M
YoY Change -12.71% 36.36% -31.26%
Interest Expense -$9.000K $55.00K -$20.00K
YoY Change -55.0% -22.54% -300.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.325M -$27.13M -$6.100M
YoY Change -12.7% 36.12% -31.07%
Income Tax
% Of Pretax Income
Net Earnings -$5.325M -$27.13M -$6.100M
YoY Change -12.7% 36.15% -31.07%
Net Earnings / Revenue -29.98% -40.22% -39.48%
Basic Earnings Per Share -$0.40
Diluted Earnings Per Share -$77.96K -$0.40 -$98.58K
COMMON SHARES
Basic Shares Outstanding 68.29M shares 67.19M shares 61.79M shares
Diluted Shares Outstanding 67.19M shares

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.22M $28.22M $16.70M
YoY Change 68.98% 68.98% -11.22%
Cash & Equivalents $28.22M $16.70M
Short-Term Investments
Other Short-Term Assets $1.859M $1.859M $1.150M
YoY Change 61.65% 61.65% 15.0%
Inventory $13.60M $13.60M $11.68M
Prepaid Expenses
Receivables $5.226M $3.126M $2.694M
Other Receivables $2.100M $2.100M $900.0K
Total Short-Term Assets $48.91M $48.91M $32.22M
YoY Change 51.79% 51.78% -3.88%
LONG-TERM ASSETS
Property, Plant & Equipment $7.355M $7.355M $3.206M
YoY Change 129.41% 66.03% -14.85%
Goodwill
YoY Change
Intangibles $857.0K $1.082M
YoY Change -20.79% -17.47%
Long-Term Investments
YoY Change
Other Assets $723.0K $723.0K $625.0K
YoY Change 15.68% 14.76% -17.98%
Total Long-Term Assets $8.935M $8.935M $6.139M
YoY Change 45.54% 45.52% -8.77%
TOTAL ASSETS
Total Short-Term Assets $48.91M $48.91M $32.22M
Total Long-Term Assets $8.935M $8.935M $6.139M
Total Assets $57.84M $57.84M $38.36M
YoY Change 50.79% 50.78% -4.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.42M $10.42M $9.445M
YoY Change 10.35% 10.3% -1.88%
Accrued Expenses $6.481M $7.009M $6.133M
YoY Change 5.67% 4.3% 38.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $20.00K $20.00K $30.00K
YoY Change -33.33% -33.33% -88.46%
Total Short-Term Liabilities $17.61M $17.61M $16.48M
YoY Change 6.9% 6.88% 9.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $20.00K
YoY Change -100.0% -100.0% 0.0%
Other Long-Term Liabilities $8.500M $8.500M $5.440M
YoY Change 56.25% 56.25% 15.25%
Total Long-Term Liabilities $8.500M $8.500M $5.460M
YoY Change 55.68% 55.68% 15.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.61M $17.61M $16.48M
Total Long-Term Liabilities $8.500M $8.500M $5.460M
Total Liabilities $26.11M $26.11M $21.93M
YoY Change 19.05% 19.07% 10.77%
SHAREHOLDERS EQUITY
Retained Earnings -$169.0M -$141.8M
YoY Change 19.13% 16.35%
Common Stock $68.00K $62.00K
YoY Change 9.68% 3.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $31.73M $31.73M $16.42M
YoY Change
Total Liabilities & Shareholders Equity $57.84M $57.84M $38.36M
YoY Change 50.79% 50.78% -4.69%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$5.325M -$27.13M -$6.100M
YoY Change -12.7% 36.15% -31.07%
Depreciation, Depletion And Amortization $262.0K $890.0K $280.0K
YoY Change -6.43% 2.18% 3.7%
Cash From Operating Activities -$4.944M -$24.16M $20.00K
YoY Change -24820.0% 127.95% -103.28%
INVESTING ACTIVITIES
Capital Expenditures -$2.000K -$409.0K $30.00K
YoY Change -106.67% 192.14% -110.71%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$2.000K -$409.0K $10.00K
YoY Change -120.0% 147.88% -96.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $26.74M
YoY Change 450.66%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 63.00K $36.09M 1.180M
YoY Change -94.66% 317.27% 337.04%
NET CHANGE
Cash From Operating Activities -4.944M -$24.16M 20.00K
Cash From Investing Activities -2.000K -$409.0K 10.00K
Cash From Financing Activities 63.00K $36.09M 1.180M
Net Change In Cash -4.883M $11.52M 1.210M
YoY Change -503.55% -644.78% -1828.57%
FREE CASH FLOW
Cash From Operating Activities -$4.944M -$24.16M $20.00K
Capital Expenditures -$2.000K -$409.0K $30.00K
Free Cash Flow -$4.942M -$23.75M -$10.00K
YoY Change 49320.0% 127.09% -96.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001386570
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37752
CY2021 dei Entity Registrant Name
EntityRegistrantName
CHROMADEX CORPORATION
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2940963
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
10900 Wilshire Blvd
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90024
CY2021 dei City Area Code
CityAreaCode
310
CY2021 dei Local Phone Number
LocalPhoneNumber
388-6706
CY2021 dei Auditor Location
AuditorLocation
New York, NY
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
CDXC
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
473500000 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
68309365 shares
CY2021 dei Auditor Firm
AuditorFirmId
688
CY2021 dei Auditor Name
AuditorName
Marcum LLP
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
200000 USD
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
200000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28219000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16697000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
65000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
189000 USD
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
2100000 USD
CY2020Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
900000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5226000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2694000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
13601000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
11683000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1859000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1145000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
48905000 USD
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
3003000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
32219000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
31000 USD
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
161000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
3206000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
857000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1082000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4352000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1226000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
723000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
625000 USD
CY2021Q4 us-gaap Assets
Assets
57840000 USD
CY2020Q4 us-gaap Assets
Assets
38358000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10423000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9445000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6481000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6133000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
528000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
589000 USD
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
20000 USD
CY2020Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
278000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17613000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16476000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4346000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4441000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4154000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
997000 USD
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
20000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
26113000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
21934000 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68126000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68126000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61881000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61881000 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
68000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
62000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
200614000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
158190000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168953000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141825000 USD
CY2021Q4 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
-2000 USD
CY2020Q4 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
-3000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31727000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
16424000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57840000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38358000 USD
CY2021 us-gaap Revenues
Revenues
67449000 USD
CY2020 us-gaap Revenues
Revenues
59257000 USD
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
25959000 USD
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
23983000 USD
CY2021 us-gaap Gross Profit
GrossProfit
41490000 USD
CY2020 us-gaap Gross Profit
GrossProfit
35274000 USD
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28352000 USD
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20948000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3832000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3415000 USD
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36379000 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30765000 USD
CY2021 us-gaap Operating Expenses
OperatingExpenses
68563000 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
55128000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-27073000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-19854000 USD
CY2021 us-gaap Interest Expense
InterestExpense
55000 USD
CY2020 us-gaap Interest Expense
InterestExpense
71000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27128000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19925000 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67185000 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67185000 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61067000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61067000 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
20445000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
100000 USD
CY2020 cdxc Issuance Of Common Stock Net Of Offering Costs Amount
IssuanceOfCommonStockNetOfOfferingCostsAmount
4856000 USD
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4115000 USD
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6936000 USD
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
-3000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19925000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
16424000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
400000 USD
CY2021 cdxc Issuance Of Common Stock Net Of Offering Costs Amount
IssuanceOfCommonStockNetOfOfferingCostsAmount
26740000 USD
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9495000 USD
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6195000 USD
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
1000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27128000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31727000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27128000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19925000 USD
CY2021 us-gaap Depreciation
Depreciation
890000 USD
CY2020 us-gaap Depreciation
Depreciation
871000 USD
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
225000 USD
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
243000 USD
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
511000 USD
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
399000 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
6195000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
6936000 USD
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
46000 USD
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
36000 USD
CY2021 cdxc Loss From Investment In Long Term Assets
LossFromInvestmentInLongTermAssets
0 USD
CY2020 cdxc Loss From Investment In Long Term Assets
LossFromInvestmentInLongTermAssets
395000 USD
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
4000 USD
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-108000 USD
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-94000 USD
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
2578000 USD
CY2020 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
555000 USD
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1918000 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
148000 USD
CY2021 cdxc Implementation Costs For Cloud Computing Arrangement
ImplementationCostsForCloudComputingArrangement
278000 USD
CY2020 cdxc Implementation Costs For Cloud Computing Arrangement
ImplementationCostsForCloudComputingArrangement
142000 USD
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
810000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
427000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
978000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-181000 USD
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
348000 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1717000 USD
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-95000 USD
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
568000 USD
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-116000 USD
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
106000 USD
CY2021 cdxc Increase Decrease In Principal Payments On Operating Leases
IncreaseDecreaseInPrincipalPaymentsOnOperatingLeases
541000 USD
CY2020 cdxc Increase Decrease In Principal Payments On Operating Leases
IncreaseDecreaseInPrincipalPaymentsOnOperatingLeases
591000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24163000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10600000 USD
CY2021 cdxc Purchases Of Leasehold Improvements And Equipment
PurchasesOfLeaseholdImprovementsAndEquipment
409000 USD
CY2020 cdxc Purchases Of Leasehold Improvements And Equipment
PurchasesOfLeaseholdImprovementsAndEquipment
124000 USD
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
18000 USD
CY2021 cdxc Investment In Other Long Term Assets
InvestmentInOtherLongTermAssets
0 USD
CY2020 cdxc Investment In Other Long Term Assets
InvestmentInOtherLongTermAssets
23000 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-409000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-165000 USD
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26740000 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4856000 USD
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9495000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4115000 USD
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
110000 USD
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
49000 USD
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
31000 USD
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
272000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36094000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8650000 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11522000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2115000 USD
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
200000 USD
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
200000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16697000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18812000 USD
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
200000 USD
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
200000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28219000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16697000 USD
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1000 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
13000 USD
CY2021 cdxc Right Of Use Assets And Operating Lease Liabilities Incurred Due To Lease Amendment
RightOfUseAssetsAndOperatingLeaseLiabilitiesIncurredDueToLeaseAmendment
3637000 USD
CY2020 cdxc Right Of Use Assets And Operating Lease Liabilities Incurred Due To Lease Amendment
RightOfUseAssetsAndOperatingLeaseLiabilitiesIncurredDueToLeaseAmendment
734000 USD
CY2021 cdxc Finance Lease Obligation Incurred For Purchase Of Computer Equipment And Software
FinanceLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware
0 USD
CY2020 cdxc Finance Lease Obligation Incurred For Purchase Of Computer Equipment And Software
FinanceLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware
47000 USD
CY2021 cdxc Retirement Of Fully Depreciated Equipment Cost
RetirementOfFullyDepreciatedEquipmentCost
0 USD
CY2020 cdxc Retirement Of Fully Depreciated Equipment Cost
RetirementOfFullyDepreciatedEquipmentCost
5000 USD
CY2021 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
0 USD
CY2020 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
5000 USD
CY2021 us-gaap Nature Of Operations
NatureOfOperations
Nature of Business<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex Analytics, Inc., ChromaDex Asia Limited, ChromaDex Europa B.V. and ChromaDex Sağlik Ürünleri Anonim Şirketi (collectively, “ChromaDex”, the “Company”) are a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme which is found in every cell of human bodies and levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient NIAGEN®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent and/or licensed rights portfolio. ChromaDex delivers NIAGEN® as the sole active ingredient in its consumer product TRU NIAGEN®. The Company also has an analytical reference standards and services segment, which focuses on natural product fine chemicals, known as phytochemicals, and related chemistry services. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 15, 2021, Healthspan Research, LLC was dissolved. Prior to its dissolution, Healthspan Research, LLC contributed its assets and liabilities to ChromaDex Inc.</span></div>
CY2021 us-gaap Use Of Estimates
UseOfEstimates
Use of accounting estimates: The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27100000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28200000 USD
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
200000 USD
CY2021 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Certain prior period results have been reclassified to be consistent with the current period presentation.</span>
CY2021 cdxc Shipping And Handling Fees
ShippingAndHandlingFees
336000 USD
CY2020 cdxc Shipping And Handling Fees
ShippingAndHandlingFees
278000 USD
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
200000 USD
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and trade receivables. Cash and cash equivalents, consist of bank deposits or highly liquid investment-grade debt instruments with an original maturity of three months of less when purchased pursuant to the Company’s investment policy. U.S. bank accounts at each institution are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. As of December 31, 2021, the Company had approximately $26.0 million in uninsured cash deposits in U.S. bank accounts. The Company, however, believes it has very little credit risk exposure for its cash and cash equivalents. All uninsured U.S. bank deposits are held at high quality credit institutions. The Company’s trade receivables are derived from sales to its customers. The Company assess credit risk of its customers through quantitative and qualitative analysis. From this analysis, the Company establishes credit limits and manages the risk exposure. The Company, however, incurs credit losses due to bankruptcy or other failure of the customer to pay.</span>
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
26000000 USD
CY2021 cdxc Straight Line Method
StraightLineMethod
P10Y
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2021 us-gaap Advertising Expense
AdvertisingExpense
12500000 USD
CY2020 us-gaap Advertising Expense
AdvertisingExpense
7400000 USD
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67185000 shares
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27128000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19925000 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67185000 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61067000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61067000 shares
CY2021 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
115000 shares
CY2020 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
0 shares
CY2021 cdxc Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
200000 shares
CY2020 cdxc Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
200000 shares
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6823000 USD
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2358000 USD
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
4131000 USD
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
5718000 USD
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2131000 USD
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3065000 USD
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
516000 USD
CY2020Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
542000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
13601000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
11683000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2132000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1907000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
857000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1082000 USD
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
225000 USD
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
243000 USD
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
4544000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
3654000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
186000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
158000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
154000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
151000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
151000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
57000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
857000 USD
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
7547000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
6860000 USD
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
3003000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
3206000 USD
CY2021 us-gaap Depreciation
Depreciation
890000 USD
CY2020 us-gaap Depreciation
Depreciation
871000 USD
CY2021Q2 cdxc Operating Lease Liability Fair Value Of Increase Decrease Due To Lease Modification
OperatingLeaseLiabilityFairValueOfIncreaseDecreaseDueToLeaseModification
2200000 USD
CY2021Q2 cdxc Operating Lease Right Of Use Asset Fair Value Of Increase Decrease Due To Lease Modification
OperatingLeaseRightOfUseAssetFairValueOfIncreaseDecreaseDueToLeaseModification
2200000 USD
CY2021Q2 cdxc Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
1 renewal_option
CY2021Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q4 cdxc Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
1 renewal_option
CY2021Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q4 cdxc Operating Lease Liability Fair Value Of Increase Decrease Due To Lease Modification
OperatingLeaseLiabilityFairValueOfIncreaseDecreaseDueToLeaseModification
1400000 USD
CY2021Q4 cdxc Operating Lease Right Of Use Asset Fair Value Of Increase Decrease Due To Lease Modification
OperatingLeaseRightOfUseAssetFairValueOfIncreaseDecreaseDueToLeaseModification
1400000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4400000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1200000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4700000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1600000 USD
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
625000 USD
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
501000 USD
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
195000 USD
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
182000 USD
CY2021 cdxc Total Operating Lease Expenses
TotalOperatingLeaseExpenses
820000 USD
CY2020 cdxc Total Operating Lease Expenses
TotalOperatingLeaseExpenses
683000 USD
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
249000 USD
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
253000 USD
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1069000 USD
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
936000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.059
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
694000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
949000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1159000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1141000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
906000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
677000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5526000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
844000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4682000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
528000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4154000 USD
CY2021 us-gaap Payments Of Derivative Issuance Costs
PaymentsOfDerivativeIssuanceCosts
110000 USD
CY2020 us-gaap Payments Of Derivative Issuance Costs
PaymentsOfDerivativeIssuanceCosts
49000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.252
CY2021Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
59000 USD
CY2019Q1 cdxc Advance Payments For Future Performance Obligations
AdvancePaymentsForFuturePerformanceObligations
4000000 USD
CY2020Q4 cdxc Advance Payments For Future Performance Obligations
AdvancePaymentsForFuturePerformanceObligations
1000000 USD
CY2019Q1 cdxc Advance Payments For Future Performance Obligations
AdvancePaymentsForFuturePerformanceObligations
4000000 USD
CY2020Q4 cdxc Advance Payments For Future Performance Obligations
AdvancePaymentsForFuturePerformanceObligations
1000000 USD
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
95000 USD
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
432000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4346000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4441000 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.048
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.057
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.018
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.014
CY2021 cdxc Change In State Tax Rate
ChangeInStateTaxRate
0.001
CY2020 cdxc Change In State Tax Rate
ChangeInStateTaxRate
0.001
CY2021 cdxc Effective Income Tax Rate Reconciliation Tax Expirations Of Net Operating Losses
EffectiveIncomeTaxRateReconciliationTaxExpirationsOfNetOperatingLosses
-0.028
CY2020 cdxc Effective Income Tax Rate Reconciliation Tax Expirations Of Net Operating Losses
EffectiveIncomeTaxRateReconciliationTaxExpirationsOfNetOperatingLosses
0.003
CY2021 cdxc Effective Income Tax Rate Reconciliation Tax Change In Stock Options And Restricted Stock
EffectiveIncomeTaxRateReconciliationTaxChangeInStockOptionsAndRestrictedStock
0.049
CY2020 cdxc Effective Income Tax Rate Reconciliation Tax Change In Stock Options And Restricted Stock
EffectiveIncomeTaxRateReconciliationTaxChangeInStockOptionsAndRestrictedStock
-0.003
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.298
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
36136000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28496000 USD
CY2021Q4 cdxc Deferred Tax Assets Stock Options And Restricted Stock
DeferredTaxAssetsStockOptionsAndRestrictedStock
4805000 USD
CY2020Q4 cdxc Deferred Tax Assets Stock Options And Restricted Stock
DeferredTaxAssetsStockOptionsAndRestrictedStock
5051000 USD
CY2021Q4 cdxc Deferred Tax Assets Tax Interest Expense
DeferredTaxAssetsTaxInterestExpense
244000 USD
CY2020Q4 cdxc Deferred Tax Assets Tax Interest Expense
DeferredTaxAssetsTaxInterestExpense
220000 USD
CY2021Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
399000 USD
CY2020Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
272000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
17000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
50000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1073000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1190000 USD
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
880000 USD
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5000 USD
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
74000 USD
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
32000 USD
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
95000 USD
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
85000 USD
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
85000 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
96000 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43808000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35497000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
43363000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35244000 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
445000 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
253000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
445000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
253000 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
445000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
253000 USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8100000 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
43300000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
35200000 USD
CY2021 us-gaap Tax Cuts And Jobs Act Of2017 Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
9300000 USD
CY2020 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
9300000 USD
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
2100000 USD
CY2020Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
900000 USD
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.67
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Share Price
SharePrice
3.74
CY2021Q4 us-gaap Share Price
SharePrice
3.74
CY2021Q4 us-gaap Share Price
SharePrice
3.74
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
6195000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
6936000 USD
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9400000 USD
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
100000 USD
CY2021Q4 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
19710000 USD
CY2021Q4 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
3500000 USD
CY2021Q4 us-gaap Purchase Obligation
PurchaseObligation
23210000 USD
CY2021 us-gaap Royalty Expense
RoyaltyExpense
1800000 USD
CY2020 us-gaap Royalty Expense
RoyaltyExpense
1900000 USD
CY2019Q3 us-gaap Accounts Receivable From Securitization
AccountsReceivableFromSecuritization
1600000 USD
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 reportable_segment
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 reportable_segment
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 reportable_segment
CY2021 us-gaap Revenues
Revenues
67449000 USD
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
25959000 USD
CY2021 us-gaap Gross Profit
GrossProfit
41490000 USD
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28352000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3832000 USD
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36379000 USD
CY2021 us-gaap Operating Expenses
OperatingExpenses
68563000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-27073000 USD
CY2020 us-gaap Revenues
Revenues
59257000 USD
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
23983000 USD
CY2020 us-gaap Gross Profit
GrossProfit
35274000 USD
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20948000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3415000 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30765000 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
55128000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-19854000 USD
CY2021 us-gaap Revenues
Revenues
67449000 USD
CY2020 us-gaap Revenues
Revenues
59257000 USD
CY2021 us-gaap Proceeds From Customers
ProceedsFromCustomers
19800000 USD
CY2020 us-gaap Proceeds From Customers
ProceedsFromCustomers
20000000.0 USD

Files In Submission

Name View Source Status
0001628280-22-006041-index-headers.html Edgar Link pending
0001628280-22-006041-index.html Edgar Link pending
0001628280-22-006041.txt Edgar Link pending
0001628280-22-006041-xbrl.zip Edgar Link pending
cdxc-20211231.htm Edgar Link pending
cdxc-20211231.xsd Edgar Link pending
cdxc-20211231_cal.xml Edgar Link unprocessable
cdxc-20211231_def.xml Edgar Link unprocessable
cdxc-20211231_g1.jpg Edgar Link pending
cdxc-20211231_g2.jpg Edgar Link pending
cdxc-20211231_g3.jpg Edgar Link pending
cdxc-20211231_htm.xml Edgar Link completed
cdxc-20211231_lab.xml Edgar Link unprocessable
cdxc-20211231_pre.xml Edgar Link unprocessable
cdxcq4202110kexhibit231.htm Edgar Link pending
cdxcq4202110kexhibit311.htm Edgar Link pending
cdxcq4202110kexhibit312.htm Edgar Link pending
cdxcq4202110kexhibit321.htm Edgar Link pending
chromadex-amendedandrestat.htm Edgar Link pending
chromadex-nestecsupplyagre.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_0.jpg Edgar Link pending
image_01.jpg Edgar Link pending
image_1.jpg Edgar Link pending
leasedatednovember242021by.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
secondmodificationtobusine.htm Edgar Link pending
Show.js Edgar Link pending
subsidiariesofchromadexcor.htm Edgar Link pending